BridgeBio Oncology CEO shares withheld for taxes

BridgeBio Oncology Therapeutics, Inc. reported that President and CEO Pedro Beltran had 1,047 shares of Common Stock withheld by the company at $7.80 per share to cover tax obligations from vesting restricted stock units.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. reported that President and CEO Pedro Beltran had 1,047 shares of Common Stock withheld by the company at $7.80 per share to cover tax obligations from vesting restricted stock units. After this withholding, he directly holds 44,576 shares of Common Stock. This was a tax-withholding disposition, not an open-market sale.

Insider Trade Summary

Exercise Price or Tax Liability: 1,047 shares

Exercise Price or Tax Liability 1 txn

Insider Beltran Pedro

Role President and CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,047	$7.80	$8K

Holdings After Transaction: Common Stock — 44,576 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

Key Figures

Shares withheld for taxes: 1,047 shares Withholding price: $7.80 per share Shares held after transaction: 44,576 shares

3 metrics

Shares withheld for taxes 1,047 shares Common Stock withheld to satisfy tax obligations on RSU vesting

Withholding price $7.80 per share Value per share for tax-withholding disposition

Shares held after transaction 44,576 shares Direct Common Stock holdings of CEO Pedro Beltran after withholding

Key Terms

restricted stock units, tax withholding obligations, Common Stock, tax-withholding disposition

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations"

Common Stock financial

"shares of the Issuer's Common Stock withheld by the Issuer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BridgeBio Oncology (BBOT) report for its CEO?

BridgeBio Oncology reported a tax-related share withholding for its CEO. The company withheld 1,047 shares of Common Stock to cover Pedro Beltran’s tax obligations arising from vesting restricted stock units, rather than an open-market purchase or sale.

How many BridgeBio Oncology (BBOT) shares were withheld for the CEO’s taxes?

A total of 1,047 shares of BridgeBio Oncology Common Stock were withheld. The shares were valued at $7.80 each and were retained by the company specifically to satisfy Pedro Beltran’s tax withholding obligations tied to restricted stock unit vesting.

Did the BridgeBio Oncology (BBOT) CEO sell shares in the market in this Form 4?

The CEO did not sell shares in the open market. The Form 4 shows a tax-withholding disposition, where 1,047 shares were withheld by the company to pay taxes on vesting restricted stock units, a routine administrative transaction.

What are Pedro Beltran’s BridgeBio Oncology (BBOT) holdings after this transaction?

Following the tax-withholding transaction, Pedro Beltran directly holds 44,576 shares of BridgeBio Oncology Common Stock. This figure reflects his position after the company withheld 1,047 shares to satisfy tax obligations from restricted stock unit vesting.

What does transaction code F mean in the BridgeBio Oncology (BBOT) Form 4?

Transaction code F indicates a tax-withholding disposition. In this case, BridgeBio Oncology withheld 1,047 shares of Common Stock from CEO Pedro Beltran to cover tax liabilities associated with the vesting of his restricted stock units, rather than a discretionary trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 06:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beltran Pedro

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		F		1,047(1)	D	$7.8	44,576	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Aaron Chan, Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)